A phase 1 trial tested the experimental obesity medication to evaluate the pharmacokinetics and safety of immediate- and modified-release formulations of danuglipron. The study enrolled healthy adults and assessed four formulations, according to clinicaltrials.gov.
“To date, study results have demonstrated a pharmacokinetic profile supportive of once-daily dosing with a safety profile consistent with prior danuglipron studies including no liver enzyme elevations observed in more than 1,400 study participants,” Pfizer said in a news release.
The drugmaker said it will conduct dose optimization studies in the second half of 2024.
The FDA has approved 10 GLP-1 receptor agonist medications, which treat diabetes, weight loss and serious heart conditions. Currently, the only approved oral formulation is Novo Nordisk’s Rybelsus (semaglutide), which is indicated for Type 2 diabetes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
